
KEYNOTE-826 trial met its dual primary endpoints
Survival benefit with first-line pembrolizumab plus chemotherapy in persistent, recurrent or metastatic cervical cancer
Survival benefit with first-line pembrolizumab plus chemotherapy in persistent, recurrent or metastatic cervical cancer
Immune chemo-sensitisation results show potential for this approach in the treatment of advanced CRC, but greater understanding of response characteristics is required in future clinical trials
Manageable toxicity profile and signs of clinical benefit seen with gavocabtagene autoleucel in treatment-refractory mesothelin-expressing solid tumours
The ESMO Congress 2021 has started today with three sessions on developmental therapeutics, including immunotherapy. The overarching theme in these sessions is the improvement of checkpoint inhibitor-based immunotherapy and a new flavour of synthetic lethality in molecularly pre-defined solid tumours.
Genomic landscaping suggests molecular divergence between cancer subtypes and across disease stages, but molecular similarities between White and Asian populations
Prospective evidence from a multicentre study support the need for a more personalised immuno-oncology approach based on sex and gender differences
Preliminary data indicate tolerability and disease control with bexmarilimab in hard-to-treat solid tumours
Shared interests, mutual gain, flexibility and trust are key to building win–win partnerships in drug development.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.